Highlights

  • Optiscan has filed two FDA 510(k) submissions — InVue for intra-operative surgical imaging and InForm for pathology laboratory use — both filed in October 2026 with clearances targeted from October 2027.
  • The company launched InSpecta, its first own-brand clinical product, in the US veterinary market in July 2026, demonstrating the ability to take its own product to market.
  • InVue addresses the significant clinical problem of post-surgical re-excision in breast-conserving surgery, where approximately 25 to 30 per cent of patients currently require a second procedure.
  • The underlying imaging core sits inside two cleared partner-branded devices from Pentax and Carl Zeiss, providing regulatory and Manufacturing precedents that support the FDA submissions.

Optiscan Imaging Limited (ASX:OIL) has reached a pivotal moment in its transition from a technology supplier to an independent medical device company. Following three decades of building its confocal endomicroscopy platform as the underlying core within partner-branded products from Pentax and Carl Zeiss, the company has filed two FDA 510(k) submissions for its own branded human devices and launched its first own-brand clinical product in the US veterinary market.

The Clinical Problem and Optiscan's Solution

The key unmet need that InVue addresses is the gap between when surgeons make Margin decisions during cancer resection and when the histopathology results that confirm those decisions are available. In conventional practice, tissue removed during surgery is processed and read by a pathologist over a period of two to seven days — well after the surgical incision is closed and the patient has been discharged. Approximately 25 to 30 per cent of breast-conserving surgery patients return to the operating theatre for re-excision because the initial margins were found to be inadequate.

Optiscan's approach delivers a near-histology cellular image on screen within seconds while the patient is still on the operating table, allowing surgeons to identify positive margins and address them immediately. The technology uses a miniaturised confocal probe that images tissue at the probe tip, achieving sub-cellular resolution without the delays of conventional pathology. The imaging platform also integrates naturally with digital workflows, as images are created digitally at capture without the need for glass slides, scanners, or additional digitisation steps.

Two FDA Submissions and the Clearance Pathway

InVue, the intra-operative surgical device, was filed on 5 October 2026. InForm, the pathology laboratory device, was filed on 1 October 2026. Both submissions seek a general, tissue-agnostic imaging indication through the 510(k) pathway, which requires the applicant to demonstrate substantial equivalence to a legally marketed predicate device. Optiscan's submissions draw on its own predicates — specifically the Pentax and Zeiss products that contain its core — as well as other cleared confocal endomicroscopy devices. The company's existing quality management system and manufacturing have been exercised through the OEM programmes and the InSpecta launch.

The FDA submissions follow formal pre-submission Q-Sub meetings held in May and November 2025 for InVue and written feedback in March 2026 for InForm. The constructive engagement in these meetings, combined with the existence of cleared predicates using Optiscan's core technology, provides the company with reasonable confidence in the pathway. Clearances are targeted from October 2027, subject to FDA review timing. The commercial model is designed around console placements with recurring consumable Revenue from sterile single-use sheaths and annual service contracts.

Key Insights

Optiscan has accumulated more than three decades of engineering Investment and clinical validation through its OEM relationships, which now serve as the foundation for its own product strategy. The company's milestone sequence ahead involves appointing up to five US reference sites before the end of 2026, activating those sites under authorised use arrangements in mid-2027 ahead of clearance, and beginning paid procedures and broader placements from 2028. The reference-site strategy is designed to generate clinical and economic evidence that supports hospital value analysis committee decisions at a later stage.

Questions and Answers